Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Castagnetti

Showing results (131-140 of 158) with videos related to

Pageof 16
Sort By:
American Journal of Hematology|October 23, 2016
A population-based study of chronic myeloid leukemia patients treated with imatinib in first lineFausto Castagnetti, Francesco Di Raimondo, Antonio De Vivo, et al.
Annals of Hematology|October 4, 2017
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter seriesAlessandra Iurlo, Sara Galimberti, Elisabetta Abruzzese, et al.
Leukemia Research|December 9, 2015
Dasatinib first-line: Multicentric Italian experience outside clinical trialsMassimo Breccia, Fabio Stagno, Luigiana Luciano, et al.
Hematological Oncology|March 21, 2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chartGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2024
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment PlanMichele Malagola, Alessandra Iurlo, Cristina Bucelli, et al.
Hematological Oncology|July 1, 2020
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinibOlga Mulas, Giovanni Caocci, Mario Annunziata, et al.
Frontiers in Oncology|June 15, 2018
Residual Peripheral Blood CD26<sup>+</sup> Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free RemissionMonica Bocchia, Anna Sicuranza, Elisabetta Abruzzese, et al.
Leukemia Research|July 23, 2014
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survivalMassimo Breccia, Luigiana Luciano, Roberto Latagliata, et al.
International Journal of Cardiology|November 13, 2019
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitorsGiovanni Caocci, Olga Mulas, Mario Annunziata, et al.
Cancer Medicine|February 17, 2021
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA studyMichele Malagola, Alessandra Iurlo, Elisabetta Abruzzese, et al.
Pageof 16

Showing results (131-140 of 158) with videos related to

Sort By:
Pageof 16
American Journal of Hematology|October 23, 2016
A population-based study of chronic myeloid leukemia patients treated with imatinib in first lineFausto Castagnetti, Francesco Di Raimondo, Antonio De Vivo, et al.
Annals of Hematology|October 4, 2017
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter seriesAlessandra Iurlo, Sara Galimberti, Elisabetta Abruzzese, et al.
Leukemia Research|December 9, 2015
Dasatinib first-line: Multicentric Italian experience outside clinical trialsMassimo Breccia, Fabio Stagno, Luigiana Luciano, et al.
Hematological Oncology|March 21, 2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chartGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2024
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment PlanMichele Malagola, Alessandra Iurlo, Cristina Bucelli, et al.
Hematological Oncology|July 1, 2020
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinibOlga Mulas, Giovanni Caocci, Mario Annunziata, et al.
Frontiers in Oncology|June 15, 2018
Residual Peripheral Blood CD26<sup>+</sup> Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free RemissionMonica Bocchia, Anna Sicuranza, Elisabetta Abruzzese, et al.
Leukemia Research|July 23, 2014
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survivalMassimo Breccia, Luigiana Luciano, Roberto Latagliata, et al.
International Journal of Cardiology|November 13, 2019
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitorsGiovanni Caocci, Olga Mulas, Mario Annunziata, et al.
Cancer Medicine|February 17, 2021
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA studyMichele Malagola, Alessandra Iurlo, Elisabetta Abruzzese, et al.
Pageof 16